Markets

Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial

March 29, 2026 — 11:21 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).

The Type C Meeting is part of Alterity's multidisciplinary strategy to align with the FDA on readiness to initiate a pivotal Phase 3 trial in MSA. The company reported that it received written feedback supporting its plans related to both the clinical pharmacology and non-clinical development aspects of the program, reinforcing confidence in moving forward with the next stage of clinical testing.

ATH.AX was trading on the Australian Securities Exchange at A$0.0080, showing no change from the previous session.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial

Tags

Latest Articles